1. Academic Validation
  2. Intermittent hypoxia therapy ameliorates beta-amyloid pathology via TFEB-mediated autophagy in murine Alzheimer's disease

Intermittent hypoxia therapy ameliorates beta-amyloid pathology via TFEB-mediated autophagy in murine Alzheimer's disease

  • J Neuroinflammation. 2023 Oct 20;20(1):240. doi: 10.1186/s12974-023-02931-6.
Xueting Wang # 1 Yuqi Xie # 2 Guijuan Chen 2 Yapeng Lu 2 Dan Wang 2 Li Zhu 3
Affiliations

Affiliations

  • 1 Institute of Special Environmental Medicine, Co-Innovation Center of Neuroregeneration, Nantong University, No. 9, Seyuan Road, Chongchuan District, Nantong, 226009, Jiangsu, China. wangxueting@ntu.edu.cn.
  • 2 Institute of Special Environmental Medicine, Co-Innovation Center of Neuroregeneration, Nantong University, No. 9, Seyuan Road, Chongchuan District, Nantong, 226009, Jiangsu, China.
  • 3 Institute of Special Environmental Medicine, Co-Innovation Center of Neuroregeneration, Nantong University, No. 9, Seyuan Road, Chongchuan District, Nantong, 226009, Jiangsu, China. zhulizhou@ntu.edu.cn.
  • # Contributed equally.
Abstract

Background: Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder. Impaired Autophagy in plaque-associated microglia (PAM) has been reported to accelerate amyloid plaque deposition and cognitive impairment in AD pathogenesis. Recent evidence suggests that the transcription factor EB (TFEB)-mediated activation of the autophagy-lysosomal pathway is a promising treatment approach for AD. Moreover, the complementary therapy of intermittent hypoxia therapy (IHT) has been shown to upregulate Autophagy and impart beneficial effects in patients with AD. However, the effect of IHT on PAM remains unknown.

Methods: 8-Month-old APP/PS1 mice were treated with IHT for 28 days. Spatial learning memory capacity and anxiety in mice were investigated. AD pathology was determined by the quantity of nerve fibers and synapses density, numbers of microglia and neurons, Aβ plaque deposition, pro-inflammatory factors, and the content of Aβ in the brain. TFEB-mediated Autophagy was determined by western blot and qRT-PCR. Primary microglia were treated with oligomeric Aβ 1-42 (oAβ) combined with IHT for mechanism exploration. Differential genes were screened by RNA-seq. Autophagic degradation process of intracellular oAβ was traced by immunofluorescence.

Results: In this study, we found that IHT ameliorated cognitive function by attenuating neuronal loss and axonal injury in an AD animal model (APP/PS1 mice) with beta-amyloid (Aβ) pathology. In addition, IHT-mediated neuronal protection was associated with reduced Aβ accumulation and plaque formation. Using an in vitro PAM model, we further confirmed that IHT upregulated autophagy-related proteins, thereby promoting the Aβ autophagic degradation by PAM. Mechanistically, IHT facilitated the nuclear localization of TFEB in PAM, with TFEB activity showing a positive correlation with Aβ degradation by PAM in vivo and in vitro. In addition, IHT-induced TFEB activation was associated with the inhibition of the AKT-MAPK-mTOR pathway.

Conclusions: These results suggest that IHT alleviates neuronal damage and neuroinflammation via the upregulation of TFEB-dependent Aβ clearance by PAM, leading to improved learning and memory in AD mice. Therefore, IHT may be a promising non-pharmacologic therapy in complementary medicine against AD.

Keywords

Alzheimer's disease; Autophagy; Beta-amyloid degradation; Plaque-associated microglia; Transcription factor EB.

Figures
Products